Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

[Clinical use of statins and cholesterol goals in patients with several cardiovascular risk factors].

Gómez-Belda A, Rodilla E, Albert A, García L, González C, Pascual JM.

Med Clin (Barc). 2003 Oct 25;121(14):527-31. Spanish.

PMID:
14599407
3.

Low-density lipoprotein-cholesterol lowering in individuals at intermediate cardiovascular risk: Percent reduction or target level?

Cesena FHY, Laurinavicius AG, Valente VA, Conceição RD, Santos RD, Bittencourt MS.

Clin Cardiol. 2018 Mar;41(3):333-338. doi: 10.1002/clc.22868. Epub 2018 Mar 25.

4.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
5.

The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease.

Ho KT, Chin KW, Ng KS, Alemao E, Rajagopalan S, Yin D.

Am J Cardiovasc Drugs. 2006;6(6):383-91.

PMID:
17192128
6.

Determinants of low-density lipoprotein cholesterol goal attainment: Insights from the CEPHEUS Pan-Asian Survey.

Wang KF, Chang CC, Wang KL, Wu CH, Chen LC, Lu TM, Lin SJ, Chiang CE.

J Chin Med Assoc. 2014 Feb;77(2):61-7. doi: 10.1016/j.jcma.2013.10.013. Epub 2013 Dec 11.

8.
9.
10.

Achieving recommended low density lipoprotein cholesterol goals and the factors associated with target achievement of hypercholesterolemia patients with rosuvastatin in primary care.

Lee JA, Sunwoo S, Kim YS, Oh HJ, Kang HC, Park KC, Sin DH, Lee SY, Yang YJ, Yu BY, Kim CM.

Curr Med Res Opin. 2013 Jul;29(7):751-60. doi: 10.1185/03007995.2013.802683.

PMID:
23647398
11.

Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).

Boytsov S, Logunova N, Khomitskaya Y; CEPHEUS II investigators.

Cardiovasc Diabetol. 2017 Dec 16;16(1):158. doi: 10.1186/s12933-017-0641-4.

12.

Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.

Daskalopoulou SS, Mikhailidis DP.

Curr Med Res Opin. 2006 Mar;22(3):511-28. Review.

PMID:
16574035
13.

Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.

Maddox TM, Borden WB, Tang F, Virani SS, Oetgen WJ, Mullen JB, Chan PS, Casale PN, Douglas PS, Masoudi FA, Farmer SA, Rumsfeld JS.

J Am Coll Cardiol. 2014 Dec 2;64(21):2183-92. doi: 10.1016/j.jacc.2014.08.041. Epub 2014 Nov 19.

14.
15.
18.
20.

A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.

Alla VM, Agrawal V, DeNazareth A, Mohiuddin S, Ravilla S, Rendell M.

Drugs. 2013 Jul;73(10):1025-54. doi: 10.1007/s40265-013-0072-9. Review.

PMID:
23754124

Supplemental Content

Support Center